Every Obesity Peptide in the Pipeline: 2026

Oral GLP-1 and Next-Gen Obesity

193+ obesity drugs in active development

The obesity drug pipeline has exploded since semaglutide's approval. As of early 2026, over 193 assets are in development targeting weight loss through incretin, amylin, glucagon, and combination pathways.

IQVIA, Outlook for Obesity in 2026

IQVIA, Outlook for Obesity in 2026

View as image

The obesity drug landscape in 2026 bears almost no resemblance to what existed five years ago. Semaglutide (Wegovy) and tirzepatide (Zepbound) proved that peptide-based drugs could produce 15-22% weight loss in clinical trials, creating a market that reached $10.1 billion in 2024. That commercial success triggered an unprecedented pipeline expansion. IQVIA counted over 193 obesity drug assets in active development as of late 2025, up from 181 just six months earlier. The race is no longer about whether peptides can treat obesity. It is about which combination of receptors, which route of administration, and which dosing frequency will define the next generation.

This tracker covers every major peptide and peptide-adjacent obesity drug in Phase 2 or Phase 3 clinical trials as of March 2026. For background on how these drugs work, the pillar article on orforglipron and the oral GLP-1 disruption explains the mechanistic landscape.

Phase 3: The Frontrunners

Retatrutide (Eli Lilly) - Triple Agonist (GLP-1/GIP/Glucagon)

Retatrutide is the most potent weight-loss peptide to reach Phase 3. It activates three receptors simultaneously: GLP-1 (appetite suppression and insulin secretion), GIP (fat metabolism and satiety), and glucagon (energy expenditure and hepatic lipid mobilization). In the Phase 2 study published in NEJM, the highest dose produced 24.2% weight loss at 48 weeks, with participants still losing weight when the study ended.^[1]

The Phase 3 TRIUMPH program confirmed these results. TRIUMPH-4 reported 28.7% mean body weight reduction at 68 weeks, the highest figure in any Phase 3 obesity trial to date. Ganamurali et al. (2026) reviewed the mechanistic basis for this superiority: the glucagon receptor component increases energy expenditure through hepatic lipid oxidation, an effect that pure GLP-1 or GLP-1/GIP agonists lack.^[2]

Remaining TRIUMPH readouts are expected through 2026. An NDA filing is anticipated in late 2026 or early 2027. This connects directly to the question explored in beyond triple agonists about whether adding a fourth receptor target could push efficacy even higher.

CagriSema (Novo Nordisk) - GLP-1 + Amylin

CagriSema combines semaglutide (GLP-1 agonist) with cagrilintide (long-acting amylin analog) in a single weekly injection. The REDEFINE 1 trial, published in NEJM, showed 22.7% mean weight loss at 68 weeks, outperforming the semaglutide-alone comparator arm.^[3]

Cagrilintide works through a distinct mechanism from GLP-1: it acts on amylin receptors in the area postrema and other brainstem regions to reduce appetite and slow gastric emptying. Carvas et al. (2025) demonstrated that cagrilintide lowers body weight through central mechanisms distinct from semaglutide, explaining the additive effect.^[4]

Gadelmawla et al. (2026) analyzed CagriSema versus semaglutide monotherapy data, confirming the superiority of the combination across multiple endpoints.^[5] Novo Nordisk has filed for FDA approval with a decision expected in late 2026. Additional REDEFINE trials (including adolescents) are ongoing.

Orforglipron (Eli Lilly) - Oral Non-Peptide GLP-1

Orforglipron is not a peptide itself but a small molecule that activates the GLP-1 receptor. It represents the most advanced attempt to replace injectable GLP-1 peptides with a daily oral pill. The ATTAIN Phase 3 program is in late-stage execution, with Rosenstock et al. (2025) publishing data showing it improved beta-cell function markers by up to 132% and enhanced insulin sensitivity in type 2 diabetes patients.^[6]

Horn et al. (2026) provided a comprehensive review of orforglipron's pharmacology, positioning it as the potential first oral small-molecule GLP-1 agonist for obesity if remaining ATTAIN readouts are positive.^[7] NDA filing is possible in late 2026. For the full story on Pfizer's competing oral GLP-1, danuglipron, which has faced significant development challenges, see the dedicated article.

Survodutide (Boehringer Ingelheim/Zealand Pharma) - Dual GLP-1/Glucagon

Survodutide combines GLP-1 and glucagon receptor agonism without GIP. Its differentiation is in metabolic-associated steatohepatitis (MASH, formerly NASH): the glucagon component mobilizes hepatic fat stores while GLP-1 reduces appetite and inflammation. Wan et al. (2024) meta-analyzed Phase 2 data showing significant reductions in body weight (-8.33 kg), BMI (-4.03 kg/m2), and waist circumference (-6.33 cm) compared to placebo.^[8]

Phase 2 achieved approximately 19% weight loss at 48 weeks. The Phase 3 SYNCHRONIZE program includes four trials: SYNCHRONIZE-1 (obesity), SYNCHRONIZE-2 (type 2 diabetes), SYNCHRONIZE-3 (MASH), and SYNCHRONIZE-4. First Phase 3 efficacy results are expected in 2026.

VK2735 (Viking Therapeutics) - Dual GLP-1/GIP

VK2735 is a dual GLP-1/GIP agonist developed by Viking Therapeutics. The subcutaneous formulation produced 14.7% weight loss at just 13 weeks in Phase 2. Bays et al. (2026) published the weekly subcutaneous data confirming significant dose-dependent weight reduction over the treatment period.^[9]

The oral formulation showed 12.2% weight loss at 13 weeks in the VENTURE-Oral Phase 2 study, one of the strongest oral weight loss results reported. The subcutaneous Phase 3 VANQUISH trial is actively enrolling. Viking is also developing an oral Phase 3 program expected to begin in 2026-2027.

Phase 2: The Next Wave

Amycretin/Zenagamtide (Novo Nordisk) - Unimolecular GLP-1/Amylin

Unlike CagriSema (which combines two separate molecules), amycretin (now called zenagamtide) is a single molecule that activates both GLP-1 and amylin receptors. Dahl et al. (2025) published Phase 2 results in The Lancet showing 14.5% weight loss at 36 weeks, with participants still losing weight at study end.^[10]

Novo Nordisk plans to initiate the Phase 3 program in early 2026 for adults with overweight or obesity. The unimolecular design offers manufacturing and dosing simplicity compared to CagriSema's co-formulation approach.

Maridebart Cafraglutide/MariTide (Amgen) - GLP-1 Agonist/GIP Antagonist

MariTide takes a contrarian approach: it activates GLP-1 receptors while blocking GIP receptors (the opposite of tirzepatide's GIP agonism). Published in NEJM, Phase 2 data showed up to 20% weight loss with once-monthly dosing at 52 weeks, without reaching a weight plateau. The monthly dosing could be a significant differentiator in a market where weekly injections are the norm. Amgen has initiated the Phase 3 MARITIME program.

Petrelintide (Roche/Zealand Pharma) - Amylin Analog

Petrelintide is the first standalone amylin analog tested as an obesity monotherapy. The ZUPREME-1 Phase 2 trial reported 10.7% weight loss at 42 weeks. While the magnitude is below GLP-1-based agents, petrelintide represents a mechanistically distinct approach that could be combined with GLP-1 agonists. Roche is deciding whether to advance to Phase 3, with a decision expected in 2026.

Mazdutide (Innovent/Eli Lilly China) - Dual GLP-1/Glucagon

Mazdutide is already approved in China (November 2024) and continues global Phase 3 development. Dong et al. (2025) published the mechanistic analysis of this dual GLP-1/glucagon agonist.^[11] Chinese Phase 3 data showed approximately 15% weight loss. The adolescent Phase 1b study demonstrated 8.78-10.99% BMI reduction at the 4-6 mg doses.

Ecnoglutide (Sciwind/Dong-A) - Long-Acting GLP-1

Ecnoglutide is a once-monthly GLP-1 agonist designed to reduce injection burden. Guo et al. (2023) published the discovery and preclinical pharmacology of ecnoglutide in Molecular Metabolism.^[12] Multiple Phase 3 trials are ongoing, primarily in China. If successful, it would offer a GLP-1 monotherapy option with monthly rather than weekly dosing.

Reading the Pipeline: What Patterns Emerge

Multi-receptor targeting is winning. The top three performers by weight loss percentage (retatrutide, CagriSema, MariTide) all target multiple receptor pathways. The incremental benefit of adding receptors appears to be real, not just theoretical. Retatrutide's triple agonism outperforms tirzepatide's dual agonism, which outperforms semaglutide's single agonism.

The amylin pathway is the next frontier. CagriSema, amycretin, and petrelintide all target amylin receptors. Amylin's appetite-suppressing mechanism is distinct from GLP-1's, operating through different brainstem circuits. This mechanistic complementarity explains why GLP-1/amylin combinations outperform GLP-1 alone.

Oral formulations are accelerating. Orforglipron, oral VK2735, and oral semaglutide (Rybelsus/Wegovy pill, approved late 2025) all target the massive population of patients who prefer pills over injections. The conversion from injectable-only to oral-available could expand the addressable market severalfold.

Monthly dosing is the next convenience target. MariTide and ecnoglutide both offer monthly injection schedules. In a market where adherence drops markedly with weekly injections, reducing frequency to monthly could improve real-world effectiveness.

The pipeline is global. Mazdutide is approved in China but not yet in the US or EU. Ecnoglutide is in Phase 3 primarily in Asia. The obesity drug pipeline is no longer US/EU-centric, and regulatory timelines now vary by geography.

For the broader context on pemvidutide's dual GLP-1/glucagon approach targeting both weight and liver disease, see the dedicated article in this cluster.

What These Drugs Still Cannot Do

The pipeline is impressive, but several challenges remain unsolved across all candidates:

Weight regain after discontinuation. Every obesity drug studied to date shows substantial weight regain when treatment stops. Semaglutide discontinuation studies documented two-thirds of lost weight returning within a year. Whether the newer multi-receptor agonists will perform differently is unknown; no Phase 3 program has yet published long-term discontinuation data.

Lean mass preservation. Weight loss from GLP-1-based drugs is approximately 25-40% lean mass (muscle and bone), not purely fat. This raises concerns about sarcopenia, bone density loss, and metabolic rate reduction, particularly in older patients. Bimagrumab, an anti-activin type II receptor antibody, showed it could reduce fat mass by 20.5% while increasing lean mass by 3.6% in Phase 2, but it is not a peptide and is not being developed for obesity monotherapy. No peptide in the current pipeline specifically addresses lean mass preservation.

Gastrointestinal tolerability. Nausea, vomiting, and diarrhea remain the most common reasons for treatment discontinuation across all GLP-1-based drugs. The dose-titration protocols used in clinical trials mitigate these effects, but real-world discontinuation rates are higher than trial rates. Whether triple agonists with glucagon activity will have better or worse GI tolerability than dual agonists is still being determined in Phase 3.

Access and cost. Current GLP-1 obesity drugs cost $1,000-$1,500 per month in the US, and insurance coverage is inconsistent. The pipeline drugs are expected to launch at similar price points. The global obesity-eligible population exceeds 650 million adults; the current manufacturing and distribution infrastructure cannot serve more than a fraction of that population, regardless of clinical efficacy.

Cardiovascular and cancer safety. Semaglutide demonstrated cardiovascular benefit in the SELECT trial. Whether the newer multi-receptor agonists share this benefit, or introduce new risks from glucagon or GIP receptor activation, is a critical open question. Long-term safety data for retatrutide, CagriSema, and the other pipeline drugs will take years to accumulate.

The Bottom Line

The obesity peptide pipeline in 2026 includes over 193 active development programs, with retatrutide (28.7% weight loss), CagriSema (22.7%), and MariTide (up to 20%) leading Phase 3. Multi-receptor targeting consistently outperforms single-receptor approaches. The amylin pathway is emerging as a key second target alongside GLP-1. Oral formulations (orforglipron, oral VK2735) and monthly dosing (MariTide, ecnoglutide) address convenience barriers. Multiple FDA decisions and late-stage readouts are expected through 2026-2027.

Frequently Asked Questions

What is the most effective obesity drug in clinical trials in 2026?

Retatrutide, Eli Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors, produced 28.7% mean body weight loss at 68 weeks in the Phase 3 TRIUMPH-4 trial. This is the highest weight loss figure ever reported in a Phase 3 obesity study. CagriSema (22.7% at 68 weeks) and MariTide (up to 20% at 52 weeks) are the next closest performers.

When will new obesity drugs be approved by the FDA?

CagriSema (Novo Nordisk) has filed for FDA approval with a decision expected in late 2026. Orforglipron (Eli Lilly) may file an NDA in late 2026 if remaining Phase 3 ATTAIN readouts are positive. Retatrutide is expected to file in late 2026 or early 2027 pending completion of the TRIUMPH program. Survodutide Phase 3 results are expected through 2026.

What obesity peptides can be taken as a pill?

Oral semaglutide (Wegovy pill) was approved for obesity in late 2025, becoming the first oral GLP-1 for weight loss. Orforglipron (Eli Lilly) is a small-molecule oral GLP-1 agonist in late Phase 3. Oral VK2735 (Viking Therapeutics) achieved 12.2% weight loss at 13 weeks in Phase 2. Danuglipron (Pfizer) is an oral GLP-1 that has faced development setbacks.

How does retatrutide compare to tirzepatide and semaglutide?

Retatrutide targets three receptors (GLP-1, GIP, glucagon) versus tirzepatide's two (GLP-1, GIP) and semaglutide's one (GLP-1). Phase 3 weight loss data shows retatrutide at 28.7%, tirzepatide at approximately 22%, and semaglutide at approximately 15%. The glucagon receptor component in retatrutide increases energy expenditure through hepatic fat oxidation, a mechanism the other two lack.

What is CagriSema and how does it work?

CagriSema combines two Novo Nordisk drugs in one weekly injection: semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog). GLP-1 and amylin suppress appetite through different brainstem circuits, producing additive weight loss. The REDEFINE 1 Phase 3 trial showed 22.7% weight loss at 68 weeks, outperforming semaglutide alone. FDA filing has been submitted with a decision expected late 2026.

What is MariTide and why is monthly dosing significant?

Maridebart cafraglutide (MariTide), developed by Amgen, is a peptide-antibody conjugate that activates GLP-1 receptors while antagonizing GIP receptors, dosed once monthly. Phase 2 showed up to 20% weight loss at 52 weeks without reaching a plateau. Monthly dosing could improve treatment adherence, as real-world data shows significant dropout rates with weekly injectable obesity drugs.